The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodiess. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.本發明係關於一種新穎的人類化、嵌合及鼠類抗體，其對於人類CC趨化因子配體20(CCL20)具有結合特異性。本發明進一步關於該等抗體之重鏈及輕鏈。本發明亦關於包含編碼該等抗體之重鏈及/或輕鏈之序列的分離核酸、重組載體及宿主細胞，及關於一種製備該等抗體之方法。本發明之抗-CCL20抗體可用於治療性應用中，供治療例如發炎性病症及自體免疫病症及癌症。
